Studies have also shown that adropin has regulatory effects on glucose and lipid homeostasis, insulin resistance, impaired glucose tolerance, diabetes, obesity, and hyperhomocysteinemia [4,6]. This evidence concerns the gene ENHO and hyperhomocysteinemia.